PMID- 36636621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230115
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 17
DP  - 2023
TI  - Polypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment.
PG  - 53-70
LID - 10.2147/OPTH.S385827 [doi]
AB  - Polypoidal choroidal vasculopathy (PCV) is a vascular disease of the choroid that 
      leads to hemorrhagic and exudative macular degeneration. It may cause significant 
      vision loss and thus affect the quality-of-life and psychological well-being. 
      Non-invasive, non-ICGA-based OCT criteria have shown reliable results to plan 
      adjunct photodynamic therapy (PDT) treatment, with the complete and consistent 
      coverage of polypoidal lesions (PL) and branching neovascular network (BNN). The 
      safety and efficacy of anti-vascular endothelial growth factor (anti-VEGF) 
      monotherapy and its combination with verteporfin PDT have been established. 
      However, treatment is still challenging due to frequent follow-ups, 
      non-availability of PDT, and need for multiple anti-VEGF injection visits that 
      increase the treatment burden and lead to patients being lost to follow-up. 
      Effective treatments that prolong intervals between injections while maintaining 
      vision and anatomical gains remain a critical unmet need. Longer acting 
      molecules, like brolucizumab, have shown non-inferiority in BCVA gains and 
      superior anatomical outcomes compared to other anti-VEGF agents. Newer therapies 
      in the pipeline to enhance the efficacy and longevity of treatment include 
      Faricimab and a port delivery system (PDS). This review summarizes the most 
      recent diagnostic and treatment approaches in PCV to offer better treatment 
      avenues.
CI  - (c) 2023 Sen et al.
FAU - Sen, Parveen
AU  - Sen P
AD  - Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil 
      Nadu India.
FAU - Manayath, George
AU  - Manayath G
AD  - Department of Retina and Vitreous Services, Aravind Eye Hospital and Postgraduate 
      Institute of Ophthalmology, Coimbatore, India.
FAU - Shroff, Daraius
AU  - Shroff D
AD  - Vitreoretinal Services, Shroff Eye Centre, New Delhi, India.
FAU - Salloju, Vineeth
AU  - Salloju V
AD  - Medical Affairs, Novartis Healthcare Private Limited, Mumbai, India.
FAU - Dhar, Priyanka
AU  - Dhar P
AD  - Medical Affairs, Novartis Healthcare Private Limited, Mumbai, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230105
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC9831529
OTO - NOTNLM
OT  - anti-vascular endothelial growth factor (anti-VEGF) agents
OT  - best-corrected visual acuity
OT  - branching neovascular network
OT  - brolucizumab
OT  - photodynamic therapy
OT  - polypoidal lesions
COIS- Vineeth Salloju and Priyanka Dhar are employees of Novartis Healthcare Private 
      Limited, India. The authors report no other conflicts of interest in this work.
EDAT- 2023/01/14 06:00
MHDA- 2023/01/14 06:01
PMCR- 2023/01/05
CRDT- 2023/01/13 02:06
PHST- 2022/08/11 00:00 [received]
PHST- 2022/12/05 00:00 [accepted]
PHST- 2023/01/13 02:06 [entrez]
PHST- 2023/01/14 06:00 [pubmed]
PHST- 2023/01/14 06:01 [medline]
PHST- 2023/01/05 00:00 [pmc-release]
AID - 385827 [pii]
AID - 10.2147/OPTH.S385827 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2023 Jan 5;17:53-70. doi: 10.2147/OPTH.S385827. eCollection 
      2023.